Bridgebio Oncology Therapeutics, Inc. (BBOT)

2.62 -0.08 (-2.96%) USD  |  NASDAQ  |  Oct 30, 16:00
2.64 +0.02 (+0.76%) After-Hours: 20:00
More

Bridgebio Oncology Therapeutics Revenue Estimates for Next Fiscal Year

Revenue Estimates for Next Fiscal Year Chart

View Revenue Estimates for Next Fiscal Year for BBOT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00

Historical Revenue Estimates for Next Fiscal Year Data

View and export this data back to 2025. Start Trial.
Date Value
October 26, 2026 --
October 25, 2026 --
October 20, 2026 --
September 17, 2026 --
September 14, 2026 --
September 11, 2026 --
September 10, 2026 --
September 09, 2026 --
August 14, 2026 --
August 13, 2026 --
August 12, 2026 --
August 11, 2026 --
July 08, 2026 --
June 18, 2026 --
June 08, 2026 --
June 02, 2026 --
June 01, 2026 --
May 14, 2026 --
May 13, 2026 --
May 12, 2026 --
May 11, 2026 --
Date Value
April 22, 2026 --
March 16, 2026 --
March 14, 2026 --
March 06, 2026 --
March 05, 2026 --
February 10, 2026 --
January 13, 2026 --
January 09, 2026 --
January 08, 2026 --
January 07, 2026 --
November 18, 2025 --
November 13, 2025 --
November 06, 2025 --
October 21, 2025 --
September 17, 2025 --
September 15, 2025 --
September 04, 2025 --
August 18, 2025 --
August 15, 2025 --
August 13, 2025 --

Revenue Estimates for Next Fiscal Year Range, Past 5 Years

View Revenue Estimates for Next Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Fiscal Year Benchmarks

View Revenue Estimates for Next Fiscal Year Benchmarks
Start Trial
Korsana Biosciences, Inc. Upgrade
IRulya Therapeutics, Inc. Upgrade
PepGen Inc. Upgrade
Q32 Bio, Inc. Upgrade
Arrowhead Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade